Minocycline Diffusion into Benign Prostatic Hyperplasia

Publisher Website
Google Scholar
Abstract
Minocycline, a broad-spectrum, highly lipid soluble tetracycline that has generated interest in the treatment of chronic prostatitis, was evaluated for its possible ability to be concentrated in benign prostatic hyperplasia. Drug levels in the prostate, plasma, fat, muscle and urine were measured in patients undergoing open prostatectomy after preoperative i.v. minocycline. The concentrations of the drug in the prostate and serum were close (4.16 vs. 3.01 .mu.g/g), while drug levels in striated muscle and fat were consistently lower (2.92 and 0.77 .mu.g/g). Higher preoperative doses of the drug yielded higher tissue levels. Drug delivery closer temporally to the operation yielded higher serum and prostatic levels as opposed to striated muscle and fat, suggesting a rapid diffusion of the drug into benign prostatic hyperplasia.